目的 探讨馥感啉口服液联合脾氨肽治疗小儿反复呼吸道感染的临床疗效。方法 选取2015年9月-2016年3月在郑州市第三人民院治疗的反复呼吸道感染患儿98例，随机分为对照组（49例）和治疗组（49例）。对照组口服脾氨肽口服冻干粉，2 mg/次，1次/d；治疗组在对照组基础上口服馥感啉口服液，10 mL/次，1~3岁患儿3次/d，4~6岁4次/d，7~12岁5次/d。两组患儿均经过3个月治疗。观察两组患儿临床疗效，比较治疗前后两组患儿临床症状改善时间、血清学指标、白细胞分类和白三烯D4（LTD4）水平。结果 治疗后，对照组临床总有效率为81.63%，显著低于治疗组的95.92%。两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组发热、咳嗽和肺部啰音消失时间均显著短于对照组（P<0.05）。治疗后，两组血清IL-1β、IL-6、和肿瘤坏死因子-α（TNF-α）水平均显著降低，胰岛素1号增长因子（IGF-1）、干扰素-γ（IFN-γ）和25-OH维生素D₃[25-（OH）D₃]水平均显著升高，同组比较差异具有统计学意义（P<0.05）；且治疗组上述血清学指标改善程度明显好于对照组（P<0.05）。治疗后，两组鼻咽分泌物中中性粒细胞、嗜酸性粒细胞和LTD4水平均显著降低，单核巨噬细胞显著升高，同组比较差异具有统计学意义（P<0.05）；且治疗组上述指标改善后水平显著优于对照组（P<0.05）。结论 馥感啉口服液联合脾氨肽治疗小儿反复呼吸道感染可有效改善临床症状，降低炎症水平，具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy of Fuganlin Oral Liquid combined with spleen aminopeptide in treatment of children with recurrent respiratory tract infection. Methods Children (98 cases) with recurrent respiratory tract infection in the Third People's Hospital of Zhengzhou from September 2015 to March 2016 were randomly divided into control (49 cases) and treatment (49 cases) groups. Children in the control group were po administered with Spleen Aminopeptide Oral Lyophilized Powder, 2 mg/time, once daily. Children in the treatment group were po administered with Fuganlin Oral Liquid on the basis of the control group, 10 mL/time, three times daily for 1-3 years old children, four times daily for 4-6 years old children, and five times daily for 7-12 years old children. Children in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, the serological indexes, the leukocyte classification and LTD4 levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.63%, which was significantly lower than 95.92% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of fever, coughing, and lung rale in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the IL-1β, IL-6 and TNF-α levels in two groups were significantly decreased, but IGF-1, IFN-γ and 25-(OH)D₃ was significantly increased, and there were differences in the same group (P < 0.05). And the serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the neutrophils, eosinophils and LTD4 levels of nasopharyngeal secretions in two groups were significantly decreased, and the mononuclear macrophage level was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the improvement levels of these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Fuganlin Oral Liquid combined with spleen aminopeptide in treatment of children with recurrent respiratory tract infection can effectively improve the clinical symptoms and reduce the inflammation level, which has a certain clinical application value.